Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tropifexor and Cenicriviroc Combination in NASH
NCT03517540Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of tropifexor, cenicriviroc in Nonalcoholic steatohepatitis (NASH), Liver Fibrosis (LF), sponsored by Novartis. Started Sep 2018; status: completed.
02
Drugs
tropifexorcenicriviroc
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT03517540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517540.